Back to Search Start Over

Oculomotor Deficits after Chemotherapy in Childhood.

Authors :
[ 1 ] Lund Univ, Dept Clin Sci, Lund, Sweden [ 2 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 3 ] Univ E London, Sch Biosci, London E15 4LZ, England [ 4 ] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London, England [ 5 ] Landspitali Univ Hosp, Dept Otorhinolaryngol, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 6 ] Skane Univ Hosp, Dept Paediat, Lund, Sweden [ 7 ] Skane Univ Hosp, Dept Otorhinolaryngol, Lund, Swede
Einarsson, Einar-Jón
Patel, Mitesh
Petersen, Hannes
Wiebe, Thomas
Magnusson, Måns
Moëll, Christian
Fransson, Per-Anders
[ 1 ] Lund Univ, Dept Clin Sci, Lund, Sweden [ 2 ] Univ Iceland, Fac Med, Reykjavik, Iceland [ 3 ] Univ E London, Sch Biosci, London E15 4LZ, England [ 4 ] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London, England [ 5 ] Landspitali Univ Hosp, Dept Otorhinolaryngol, Reykjavik, Iceland Organization-Enhanced Name(s) Landspitali National University Hospital [ 6 ] Skane Univ Hosp, Dept Paediat, Lund, Sweden [ 7 ] Skane Univ Hosp, Dept Otorhinolaryngol, Lund, Swede
Einarsson, Einar-Jón
Patel, Mitesh
Petersen, Hannes
Wiebe, Thomas
Magnusson, Måns
Moëll, Christian
Fransson, Per-Anders

Abstract

To access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Files. This article is open access.<br />Advances in the diagnosis and treatment of pediatric malignancies have substantially increased the number of childhood cancer survivors. However, reports suggest that some of the chemotherapy agents used for treatment can cross the blood brain barrier which may lead to a host of neurological symptoms including oculomotor dysfunction. Whether chemotherapy at young age causes oculomotor dysfunction later in life is unknown. Oculomotor performance was assessed with traditional and novel methods in 23 adults (mean age 25.3 years, treatment age 10.2 years) treated with chemotherapy for a solid malignant tumor not affecting the central nervous system. Their results were compared to those from 25 healthy, age-matched controls (mean age 25.1 years). Correlation analysis was performed between the subjective symptoms reported by the chemotherapy treated subjects (CTS) and oculomotor performance. In CTS, the temporal control of the smooth pursuit velocity (velocity accuracy) was markedly poorer (p<0.001) and the saccades had disproportionally shorter amplitude than normal for the associated saccade peak velocity (main sequence) (p = 0.004), whereas smooth pursuit and saccade onset times were shorter (p = 0.004) in CTS compared with controls. The CTS treated before 12 years of age manifested more severe oculomotor deficits. CTS frequently reported subjective symptoms of visual disturbances (70%), unsteadiness, light-headedness and that things around them were spinning or moving (87%). Several subjective symptoms were significantly related to deficits in oculomotor performance. To conclude, chemotherapy in childhood or adolescence can result in severe oculomotor dysfunctions in adulthood. The revealed oculomotor dysfunctions were significantly related to the subjects' self-perception of visual disturbances, dizziness, light-headedness and sensing unsteadiness. Assessments of oculomotor function may, thus, offer an objective method to track and rate the level of neurological comp

Details

Database :
OAIster
Notes :
PLoS ONE 2016, 11 (1):e0147703, English
Publication Type :
Electronic Resource
Accession number :
edsoai.ocn947198257
Document Type :
Electronic Resource